<DOC>
	<DOCNO>NCT00477893</DOCNO>
	<brief_summary>Spondyloarthropathies ( SpA ) often diagnose considerable delay ( often 8-10 year symptom onset ) , available clinical , biochemical radiological method sufficiently sensitive . TNF-a antagonist recently introduce treatment SpA , current data indicate high efficacy previously available therapy . The improved treatment option increase need improve method diagnosis , monitor prognostication disease , efficient therapy initiate optimal time point monitor optimally . Magnetic resonance imaging ( MRI ) number biomarkers promising , yet sufficiently study , method .</brief_summary>
	<brief_title>Danish Multicenter Study Adalimumab Spondyloarthritis</brief_title>
	<detailed_description>See brief summary</detailed_description>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Diagnosis spondyloarthritis accord European Spondyloarthritis Study Group ( ESSG ) criteria 2 . Clinical active disease , define BASDAI score &gt; 4 despite concurrent NSAID therapy 3 . Presence sacroiliitis conventional radiography MRI . 4 . Among issue : Age &gt; 18 year ; adequate birth control ; contraindication antiTNFatherapy , previous TNFaantagonists 1 . Previous TNFÎ± inhibitor therapy 2 . Treatment disease modify antirheumatic drug within 4 week screen 3 . Oral , intraarticular , intramuscular intravenous glucocorticoid within 4 week screen 4 . Pregnancy lactation 5 . HIV , hepatitis B C , tuberculosis , infection 6 . Malignancies 7 . Other serious concomitant disease ( uncontrolled/severe kidney , liver , haematological , gastrointestinal , endocrine , cardiovascular , pulmonary , neurological ore cerebral disease ( include demyelinate disease ) 8 . Contraindications antiTNFatherapy 9 . Contraindications MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>